WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)-- Merck (NYSE:MRK), known as MSD outside the United States and Canada, announced today that the U.S. Food and Drug Administration (FDA) approved JANUMET ® XR ...
If you have type 2 diabetes, your doctor might suggest Janumet or Janumet XR as a treatment option for you. Janumet and Janumet XR are prescription drugs that are prescribed along with exercise and a ...
Adjunct to diet and exercise to improve glycemic control in patients with type 2 diabetes who are not adequately controlled on metformin or sitagliptin alone or in patients already being treated with ...
New treatment combines DPP-4 inhibitor, linagliptin (the active ingredient in Tradjenta™ (linagliptin) tablets), and metformin in a single tablet, taken twice-daily, to lower blood sugar in adults ...
New data presented at the American Diabetes Association 70 th Annual Scientific Sessions WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)-- New data were presented at the American Diabetes Association (ADA) ...
Please provide your email address to receive an email when new articles are posted on . The FDA has approved a once-daily, fixed-dose combination therapy of the SGLT2 inhibitor canagliflozin and ...
July 27, 2012 — The European Commission has approved the combination pill containing the dipeptidyl peptidase-4 inhibitor linagliptin and metformin hydrochloride for the treatment of adults with type ...
Xigduo (AstraZeneca/Bristol-Myers Squibb), a 2-drug product for the treatment of type 2 diabetes and the first to combine metformin with a sodium-glucose ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback